EGFR and colorectal carcinoma: Because 60–80% of CRC tumors show epidermal growth factor receptor (EGFR) overexpression, which is associated with a poor prognosis in patients [6,7], anti-EGFR antibodies—such as Cetuximab [8] or Panitumumab [9] are important targeted therapies in CRC that contributed to the improved median survival, which increased from 5 months to 2 years between 1993 and 2009 [10].